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Cannabidiol efficacy and clobazam status.  
A systematic review and meta-analysis 
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Summary 
Objective: To evaluate the potential impact of concomitant clobazam (CLB) use on the efficacy of 
cannabidiol (CBD) treatment in patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome 
(LGS) using meta-analytical techniques. 
Methods: We searched for randomized, placebo-controlled, single or double-blinded trials. The pro-
portion of patients who achieved ≥50% reduction from baseline in seizure frequency during the treat-
ment period was assessed according to CLB status. Risk ratios (RRs) with 95% confidence intervals 
(95% CIs) were estimated. 
Results: Four trials were included and enrolled 714 participants, 429 for add-on CBD and 285 for 
add-on placebo groups. Among CBD treated patients, 240 (55.9%) were taking concomitant CLB 
(CLB-On) and 189 (44.1%) were not taking concomitant CLB (CLB-Off); in placebo treated patients, 
158 (55.4%) were CLB-On and 127 (44.6%) CLB-Off. The percentages of patients who had at least 
50% reduction in seizure frequency during the treatment period were 29.1% in the CBD arm and 
15.7% in the placebo group among CLB-Off patients [RR 1.80 (95% CI 1.12-2.90); p=0.015]. Among 
CBL-On patients, the ≥50% reduction in seizure frequency was found in 52.9% and 27.8% in the 
CBD and placebo groups [RR 1.85 (95% CI 1.40-2.44); p<0.001]. 
Significance: CBD was associated with a higher rate of seizure response in comparison to placebo 
when added to existing antiepileptic regimen both in patients taking and not taking concomitant CLB. 
The lack of randomization for CLB status and the limited sample size need to be considered in the 





Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are among the most severe and diffi-
cult to-treat epileptic encephalopathies and there remains the need to identify effective therapeutic 
options. Recently, randomized, placebo-controlled trials demonstrated the efficacy of a plant-de-
rived pharmaceutical formulation of purified cannabidiol (CBD) in controlling seizures in partici-
pants with DS and LGS and led to licensing the drug in patients aged 2 years and older.1,2   
Drug-drug interactions (DDIs) that can occur between CBD and clobazam (CLB) at pharmacoki-
netic and pharmacodynamic levels have, however, questioned the intrinsic antiseizure activity of 
CBD and imposed prescription limits in Europe.2,3  
To date, open-label uncontrolled studies and clinical trial simulation have not provided consistent 
findings about the clinical meaning of these interactions. The aim of this study, hence, was to ana-
lyze the impact of concomitant use of CLB on the efficacy of CBD treatment in patients with DS 
and LGS through a meta-analysis of randomized controlled trials (RCTs).  
 
2. Methods 
2.1 Search strategy. The report of this systematic review and meta-analysis was made according to 
the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement.4 We systematically searched (March week 1, 2020) MEDLINE (accessed by 
PubMed), the Cochrane Central Register of Controlled Trials (CENTRAL) and the US National In-
stitutes of Health Clinical Trials Registry (http://www.clinicaltrials.gov) (search strategies are out-
lined in electronic supplementary material). Additional data were sought in the Drug Approval 
Package and the Assessment Report of CBD by the U.S. Food & Drug Administration and the Eu-
ropean Medicines Agency/Committee for Medicinal Products for Human Use.1,2 The manufacturer 




date limitations or language restrictions. The reference lists of retrieved studies were reviewed to 
identify additional reports of relevant trials. The protocol was not registered previously.  
2.2 Eligibility criteria. Studies were selected when they met the following entry criteria: random-
ized, double or single blinded, placebo-controlled, parallel group studies with active and control 
groups receiving CBD and matched placebo, respectively, in addition to existing antiseizure medi-
cation (ASM). Participants had to meet the following criteria: any sex, any ethnicity, pediatric 
and/or adult age, diagnosis of DS or LGS and seizures uncontrolled by concomitant therapeutic reg-
imen. 
2.3 Outcome measure. The study outcome was the proportion of patients who achieved ≥50% re-
duction from baseline in seizure frequency during the treatment period. Convulsive seizures and 
drop seizures were assessed in DS and LGS trials, respectively. A convulsive seizure was defined as 
a tonic, clonic, tonic-clonic, or atonic seizure. A drop seizure was defined as an attack or spell 
(atonic, tonic, or tonic-clonic) involving the entire body, trunk, or head that led or could have led to 
a fall, injury, slumping in a chair, or hitting the patient’s head on a surface. 
2.4 Study selection, data extraction and assessment of the risk of bias. Two review authors (S.L. 
and F.B.) independently assessed studies for inclusion and extracted the following trial data: main 
study author, date of publication, methods of randomization, allocation concealment and blinding, 
duration of baseline and treatment periods, dose/s of CBD tested, number and demographics of par-
ticipants, number of participants experiencing the outcome during treatment. Any disagreement was 
resolved through discussion with a third review author (M.S.). The risk of bias of the included stud-
ies was assessed according to the recommendations of the Cochrane Collaboration.5  
2.5 Statistical analysis. Heterogeneity among the trials was assessed by the Chi squared test and 




sults were synthesized using a fixed effect model. If the probability value was ≤0.05, the heteroge-
neity was interpreted according to the I2 statistic and determined the choice of a fixed or random ef-
fects model (for I2 <40% or ≥40%, respectively).8-12 Risk ratios (RRs) with 95% confidence interval 
(CIs) were estimated through the inverse variance method. The intention-to-treat (ITT) population 
data were used. The analysis of the outcome was performed according to CLB status of patients 
(CLB-On for patients taking and CLB-Off for patients not taking concomitant CLB) and results 
presented by CBD daily dose. Reported probability values were two-sided, with significance set at 
<0.05. Data analysis was performed using STATA/IC 13.1 statistical package (StataCorp LP, Col-
lege Station, TX, USA). 
 
3. Results  
3.1 Results of the search. Three hundred and one records were identified by database and trial reg-
isters searching. Seven randomized controlled trials (RCTs) were retrieved for detailed assessment; 
one of them was a dose-ranging pharmacokinetic and safety trial (ClinicalTrials.gov number, 
NCT02091206) and two were withdrawn by the sponsor before participants were enrolled 
(NCT02318537, NCT02318563). Accordingly, four studies were eventually included in the meta-
analysis (Figure 1): two trials recruited patients with DS13,14 and two studies enrolled patients with 
LGS.15,16 
3.2 Characteristics and risk of bias of included studies. The included studies were multicenter, 
randomized, double-blind, placebo-controlled, parallel group trials. They enrolled 714 participants 
according to the ITT, 429 for add-on CBD and 285 for add-on placebo groups. The active treatment 
was a plant-derived pharmaceutical formulation of purified CBD oral solution (100 mg per millili-
ter) (Epidiolex®), which was administered as add-on treatment to the preexisting therapeutic regi-




was the most common concomitant ASM and used by 398 (55.7%) patients across the trials; CLB 
was prescribed in 204 (64.2%) and 194 (49.0%) patients in DS and LGS cohorts, respectively. 
Among CBD treated patients, 240 (55.9%) were CLB-On and 189 (44.1%) were CLB-Off; in pla-
cebo treated patients, 158 (55.4%) were CLB-On and 127 (44.6%) CLB-Off.  
All trials used adequate methods of sequence generation and allocation concealment. We rated the 
trials at low risk of performance and detection bias as blinding was ensured by matching placebo, 
and neither the investigators nor the patients knew the identity of the treatment being administered. 
The risks of attrition and selective reporting bias were judged low, and there was no suspicion of 
selective outcome reporting. All trials were sponsored by the CBD manufacturer (GW Pharmaceuti-
cals).  
3.3 Fifty percent or greater reduction in baseline seizure frequency. Across the trials, the per-
centages of patients not taking CLB who had at least 50% reduction in seizure frequency during the 
treatment period were 29.1% in the CBD arm and 15.7% in the placebo group; the corresponding 
estimated RR was 1.80 [(95% CI 1.12-2.90); p=0.015] (chi squared=3.71, df=3, p=0.294; 
I2=19.2%]; among CBL-On patients, the ≥50% reduction in seizure frequency was achieved by 
52.9% and 27.8% in the CBD and placebo groups, respectively and the corresponding RR was 1.85 
[(95% CI 1.40-2.44); p<0.001] (chi squared=0.75, df=3, p=0.860; I2=0.0%] (Figure 2A). 
The RR to achieve a ≥50% reduction in baseline seizure frequency during the treatment period with 
CBD at 10 mg/kg/day in comparison with placebo was 3.26 [(95% CI 1.25-8.46); p=0.015] (chi 
squared=0.30, df=1, p=0.586; I2=0.0%] in CLB-Off and 1.62 [(95% CI 1.08-2.42); p=0.018] (chi 
squared=0.22, df=1, p=0.635; I2=0.0%] in CLB-On patients (Figure 2B). The estimated RR for a 
50% or greater reduction in baseline seizure frequency for patients assigned to 20 mg/kg/day in 




I2=16.1%] in CLB-Off and 1.95 [(95% CI 1.47-2.59); p<0.001] (chi squared=0.95, df=3, p=0.813; 
I2=0.0%] in CLB-On subgroups (Figure 2C).  
 
4. Discussion 
Cannabidiol was associated with a higher rate of seizure response in comparison to placebo when 
added to existing ASMs at the daily dose of both 10 and 20 mg per kilogram in patients with DS 
and LGS independent of the concomitant use of CLB.  
CBD monotherapy has shown antiseizure properties in a variety of experimental settings and ther-
apy-resistant epilepsy models, showing behavioral, EEG, and neuroprotective effects in both acute 
and chronic protocols.17 CBD showed anticonvulsant activity in mouse models of DS at 100 mg/kg 
given intraperitoneally, which approximates doses found efficacious in human trials taking into ac-
count interspecies scaling and low oral bioavailability of CBD.18 
Noteworthy, pharmacokinetic and pharmacodynamic interactions can occur when CBD is adminis-
tered with other drugs. Remarkably, CBD can inhibit the catalytic activity of the cytochrome P450 
(CYP) 2C19 and determine a 2 to 4-fold increase in plasma concentrations of the active metabolite 
N-desmethylclobazam (N-CLB), which is thought to have one third to one fifth of the antiseizure 
activity of CLB.19,20 Conversely, CLB leads to an approximate 1.5-fold increase in 7-hydroxy-CBD, 
the CBD active metabolite, probably through inhibition of CYP2D6 and glucuronidation.19,20 CBD 
is also a positive allosteric modulator of gamma-aminobutyric acid (GABA)A receptors and a phar-
macodynamic interaction occurs, where co-administration of CBD further enhances GABAA-medi-
ated inhibitory activity beyond the actions of CLB and N-CLB alone.18 In the Scn1a+/- mouse model 




of the ASMs alone against thermally induced seizures when a CBD dose with intrinsic anticonvul-
sant activity was used. A lower, subthreshold dose of CBD, however, did not promote greater anti-
seizure effects despite increasing plasma CLB concentrations.18  
Taken together, these observations have led to speculate that the antiseizure efficacy of CBD can be 
- partially or totally - explained by DDIs with CLB and concomitant CLB is necessary for the activ-
ity of CBD. So far, the clinical relevance of these interactions remains largely unknown.  
In one open-label interventional trial of patients with treatment-resistant epilepsy, 51% of partici-
pants taking CLB had a greater than 50% reduction in motor seizure frequency at 12 weeks, com-
pared with 27% of those not taking CLB.21 It is interesting to note that the responder rate was 
roughly double in the CLB-On than CLB-Off cohort and the proportion of responders among pa-
tients not taking CLB approached the rate of participants shown to respond to placebo in DS and 
LGS studies.22,23 The study design, however, did not allow to demonstrate whether the efficacy of 
CBD may be attributable to CLB. Similarly, in a subgroup of patients with tuberous sclerosis com-
plex, the 50% responder rate after 3 months of CBD treatment was 58.3% in the 12 participants tak-
ing concurrent CLB compared to 33.3% in the 6 patients not taking CLB.24  
Findings from other uncontrolled studies suggested that CBD reduces seizure frequency irrespective 
of concomitant CLB use. Among 132 children and adults with treatment-resistant epilepsy receiv-
ing CBD in an open-label Expanded Access Program, there were no significant differences in sei-
zure frequency and severity reduction at 12 weeks between patients taking and not taking concomi-
tant CLB.25 In a retrospective analysis of data collected from 47 patients with refractory epilepsy 
and treated with CBD, there was no significant difference in the reduction of mean weekly seizure 
frequency between those who took concomitant CLB and those who did not, and there was no sig-




The open-label, uncontrolled design and naturalistic follow-up of the studies, however, limit the 
generalizability of results. 
In the subset of patients who were taking CLB and stiripentol (STP) at baseline in one pivotal DS 
trial, a reduction in seizure frequency occurred in 80% and 50% of the cases assigned to CBD and 
placebo, in absence of any further increase in N-CLB levels.1 As STP is a strong CYP2C19 inhibi-
tor, it can be assumed that CLB and N-CLB levels were already maximally increased by STP-in-
duced metabolic inhibition and CBD did not determine additional inhibition. Although a pharmaco-
dynamic synergism between CBD and CLB cannot be excluded, these findings suggest that CBD 
can improve seizure control without a raise in N-CLB exposure.  
A clinical trial simulation with a pharmacokinetic/pharmacodynamic model for the effect of CBD 
on drop-seizure frequency in patients with LGS has been performed under the assumptions that pa-
tients taking 10 or 20 mg CLB would have a 2- to 7-fold increase in N-CLB exposure and CLB-Off 
patients would have a reduction in drop-seizure frequency and a variability in the percent reduction 
similar to the placebo group.27 The results suggested that the effect of 20 mg/kg/day CBD on sei-
zure frequency reduction may be mostly explained by the DDI with CLB. It is however unknown 
how well mathematical modeling can reflect real-word drug and patients characteristics, including 
drug compliance and disease evolution. Furthermore, the analyses did not account for CLB dose re-
duction, which occurred in about one quarter of the patients in the CBD group.27 
The current meta-analysis of results from patients who participated in high-quality, phase III, pro-
spective, double-blinded RCTs allowed to explore the response to CBD according to concomitant 
CLB use in a more rigorous fashion than open-label research, and increase the power to identify the 
presence of a treatment effect in comparison to individual studies. Nonetheless, some shortcomings 




have introduced potential confounders, as subgroups consisted of patients allocated to CLB treat-
ment according to decision of treating physician, including individual seizure response and develop-
ment of side effects. In this regard, however, CLB-Off patients might be considered as a group 
more difficult to treat as they had failed more ASMs during their lifetime, previously tried CLB and 
had higher seizure frequency at baseline.2 Although data of patients with two different epileptic 
conditions have been pooled, all the RCTs had similar protocols and overlapping designs and our 
aim was to evaluate the overall response to CBD and impact of CLB use rather than estimate the 
percentage reduction in specific seizure types. Only four trials with limited sample size and funded 
by one single pharmaceutical company met the eligibility criteria. Additional analyses were not fea-
sible due to the lack of data on CBD, CLB and N-CLB plasma levels, and further research is war-
ranted to clarify whether and to what extent CLB may enhance CBD response. Finally, potential 
DDIs with other ASMs and impact of genetic background and polymorphisms in genes coding for 
CYPs could have not been considered. 
 
5. Conclusion 
This analysis suggests cannabidiol to have independent anti-seizure activity and efficacy irrespec-
tive of CLB administration and cannot support the current prescription restriction. Interestingly, 
concomitant CLB has been already shown to affect the safety profile of CBD and increase the inci-
dence of adverse events, mainly somnolence, sedation, and pneumonia.28,29 DDIs represent a major 
issue in clinical practice and the knowledge of their potential consequences is critically important 
for optimization of clinical decisions.  
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Figure and table legends 
Table 1: Characteristics of the included studies 
Table 2: Characteristics of the study participants  
 
Figure 1: Flow diagram of study selection process 
Figure 2: Fifty percent or greater reduction in monthly seizure frequency from baseline during the 
































placebo-controlled trial:  
▪ 4-week observational 
baseline  
▪ 14-week double-blind 
treatment period (2-week 
titration, 12-week stable 
dosing maintenance)  
▪ ≤10 days tapering-off 
▪ 4-week safety follow-up 
▪ Aged 2 to 18 years  
▪ Documented history of Dravet 
syndrome not completely con-
trolled by current ASMs 
▪ At least four convulsive sei-
zures during the 4-week base-
line period 
▪ Current treatment with one or 
more ASMs at a stable dose 
for at least 4 weeks before 
screening 
▪ Oral placebo, 
BID 












Multicenter (United States, 
Europe, Australia, Israel) 
 
Parallel-group, randomized, 
placebo-controlled trial:  
▪ 4-week observational 
baseline  
▪ 14-week double-blind 
treatment period (2-week 
titration, 12-week stable 
dosing maintenance)  
▪ ≤10 days tapering-off 
▪ 4-week safety follow-up 
▪ Aged 2 to 18 years  
▪ Documented history of Dravet 
syndrome not completely con-
trolled by current ASMs 
▪ At least four convulsive sei-
zures during the 4-week base-
line period 
▪ Current treatment with one or 
more ASMs at a stable dose 
for at least 4 weeks before 
screening 
▪ Oral placebo, 
BID 
▪ Oral CBD: 10 

















Multicenter (United States, 




placebo-controlled trial:  
▪ 4-week observational 
baseline  
▪ 14-week double-blind 
treatment period (2-week 
titration, 12-week stable 
dosing maintenance)  
▪ ≤10 days tapering-off 
▪ 4-week safety follow-up 
▪ Aged 2 to 55 years  
▪ Clinical diagnosis of Len-
nox-Gastaut syndrome (in-
cluding documented history 
of slow [<3.0 Hz] spike-and-
wave electroencephalo-
graphic pattern) and evidence 
of at least two types of gen-
eralized seizures, including 
drop seizures, for at least 6 
months 
▪ At least two drop seizures 
each week during the 4-week 
baseline period 
▪ Current treatment with one 
or more ASMs at a stable 
dose for at least 4 weeks be-
fore screening 
▪ Documented failures on at 
least two ASMs 
▪ Oral placebo, 
BID 
▪ Oral CBD: 10 















placebo-controlled trial:  
▪ 4-week observational 
baseline  
▪ 14-week double-blind 
treatment period (2-week 
titration, 12-week stable 
dosing maintenance)  
▪ ≤10 days tapering-off 
▪ 4-week safety follow-up 
▪ Aged 2 to 55 years  
▪ Clinical diagnosis of Len-
nox-Gastaut syndrome (in-
cluding documented history 
of slow [<3.0 Hz] spike-and-
wave electroencephalo-
graphic pattern) and evi-
dence of at least two types of 
generalized seizures, includ-
ing drop seizures, for at least 
6 months 
▪ At least two drop seizures 
each week during the 4-week 
baseline period 
▪ Current treatment with one 
or more ASMs at a stable 
dose for at least 4 weeks be-
fore screening 
▪ Documented failures on at 
least two ASMs 
▪ Oral placebo, 
BID 
▪ Oral CBD: 20 
mg/kg, BID 





Table 2. Characteristics of the study participants  
Abbreviations: ASM=antiseizure medication, CBD=cannabidiol, PBO=placebo, SD=standard deviation. 
 
  




















































Male sex, % 57.4 45.8 40.9 53.7 47.7 54.8 59.2 57.9 52.3 50.6 
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Figure 1. Flow diagram of study selection process 
 





Figure 2. Fifty percent or greater reduction in monthly seizure frequency from baseline dur-
ing the treatment period according to clobazam status 
 
A. Cannabidiol any dose 
 
 











Abbreviations: CBD=cannabidiol, CI=confidence interval.  
